Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Repetitive nerve stimulation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Repetitive nerve stimulation. Displaying page 1 of 1.
    EudraCT Number: 2005-004082-42 Sponsor Protocol Number: OXY-2 Start Date*: 2005-12-05
    Sponsor Name:Søren Sindrup, Dept. of Neurology, University Hospital of Odense
    Full Title: The Pharmacogenetics of Oxycodone analgesia in human experimental pain models
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-002610-14 Sponsor Protocol Number: 79835 Start Date*: 2021-09-08
    Sponsor Name:Aarhus University Hospital, Department of Neurology
    Full Title: Mestinon and Salbutamol Tolerability and Efficacy as therapy for Post-COVID-19 Myopathy - A randomized, placebo-controlled, rater and subject-blinded, 2x2 crossover study.
    Medical condition: Post-COVID-19 Myopathy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10062913 Muscle weakness conditions HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001384-37 Sponsor Protocol Number: ECU-MG-303 Start Date*: 2020-10-07
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients with Refractory Generalized Myasthenia Gravis (gMG)
    Medical condition: Refractory Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-003357-17 Sponsor Protocol Number: Ketamin_SST01 Start Date*: 2013-11-01
    Sponsor Name:Prof. Asbjørn Mohr Drewes
    Full Title: RESET Trial A randomized, double-blinded, single-centre, parallel-group, placebo-controlled, prospective trial of S-ketamine for pain treatment in chronic pancreatitis (RESET trial)
    Medical condition: Chronic Pancreatitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10009093 Chronic pancreatitis LLT
    17.1 100000004856 10033646 Acute and chronic pancreatitis HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004369-34 Sponsor Protocol Number: UMC-NMZ-SMA2011 Start Date*: 2015-04-22
    Sponsor Name:Universtiy Medical Center Utrecht
    Full Title: SPACE trial SMA and Pyridostigmine in Adults and Children; Efficacy trial Phase II, mono-center, doubleblind, placebo-controlled, crossover trial to assess efficacy of pyridostigmine in patients ...
    Medical condition: Proximal spinal muscular atrophy (SMA) is characterized by weakness of predominantly axial and proximal muscle groups and is caused by homozygous deletion of the survival motor neuron 1 (SMN1)-gene...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10068209 Spinal muscular atrophy adult onset LLT
    17.1 100000004850 10051203 Spinal muscular atrophy congenital LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005749-30 Sponsor Protocol Number: 2015-00887 Start Date*: 2016-06-23
    Sponsor Name:Karolinska Institutet
    Full Title: A randomized, doubleblind, placebo-controlled multicenter trial to evaluate the safety and efficacy of rituximab (Mabthera) in subjects with new onset myasthenia gravis; the RINOMAX study
    Medical condition: New onset myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003898-59 Sponsor Protocol Number: EFC17262 Start Date*: 2021-11-12
    Sponsor Name:SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of tolebrutinib (SAR442168) in adults with generalized myasthenia gravis (MG)
    Medical condition: Myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-005619-35 Sponsor Protocol Number: REFINE2020 Start Date*: 2021-06-07
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: SINGLE-CELL DEEP PHENOTYPING OF B LYMPHOCYTES TO PERSONALIZE IMMUNOTHERAPY IN PATIENTS WITH MYASTHENIA GRAVIS: CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RITXUXIMAB IN GENERALIZED ACHR-A...
    Medical condition: Generalized AChR-antibody positive Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004085-19 Sponsor Protocol Number: ARGX-113-2001 Start Date*: 2021-02-24
    Sponsor Name:argenx BV
    Full Title: A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of ...
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) BE (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002938-73 Sponsor Protocol Number: ARGX-113-1602 Start Date*: 2016-10-31
    Sponsor Name:Argenx BVBA
    Full Title: A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness
    Medical condition: Myasthenia Gravis who have Generalized Muscle Weakness
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000249-42 Sponsor Protocol Number: IMVT-1401-3101 Start Date*: 2022-10-12
    Sponsor Name:Immunovant Sciences GmbH
    Full Title: A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Genera...
    Medical condition: Generalized Myasthenia Gravis (gMG)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 12:58:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA